Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Open for Input on Submission until December 19, 2018)

Abemaciclib (Brand Name: TBD) for Metastatic Breast Cancer
(Open for Input on Submission until December 17, 2018)

Ixazomib (Ninlaro) for Multiple Myeloma (2nd-beyond)
(Open for Input on Submission until December 14, 2018)

Daratumumab (Darzalex) in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma
(Pending Submission as of November 29, 2018)

Nivolumab (Opdivo) for Advanced or Metastatic Hepatocellular Carcinoma
(Final Recommendation Issued as of November 29, 2018)

Pertuzumab-Trastuzumab (Perjeta-Herceptin) Combo Pack for Early Breast Cancer  
(Final Recommendation Issued as of November 29, 2018)

Abiraterone (Zytiga) for Prostate Cancer
(Pending Submission as of November 27, 2018)

Lenalidomide (Revlimid) in combination with Bortezomib and Dexamethasone for Newly Diagnosed Multiple Myeloma
(Pending Submission as of November 23, 2018)

Trastuzumab (Ogivri) for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar
(Pending Submission as of November 20, 2018)

Pembrolizumab (Keytruda) for Melanoma Adjuvant Treatment
(Pending Submission as of November 9, 2018)

 

Find a Drug Review